Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Xenon Pharmaceuticals Inc. (XENE): Biotechnology Value Fund Adds More Shares

Mark Lampert‘s Biotechnology Value Fund reported raising its stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) to 3.11 million shares, which account for 17.9% of the company’s outstanding stock, via a newly-amended 13G filing released by the Securities and Exchange Commission. Previously, the fund held 1.78 million shares or 12.3% of Xenon’s outstanding stock, according to its 13F filing for the June 30 reporting period.

As the name denotes it, Xenon Pharmaceuticals is a clinical stage biopharmaceutical company that develops various therapeutics for orphan indications. Recently, the company made a $30 million public offering of common shares, priced at $7.50 per share. Year-to-date, Xenon Pharmaceuticals’ stock is down by 4.48%. In its latest financial report, for the second quarter of 2016, the company disclosed revenue of $0.4 million and a basic loss per share of $0.42, compared to a revenue of $4.04 million and earnings per share of $0.08, for the corresponding period of the prior year.

medication, pharmacist, shelf, care, pharmaceutical, medical, day, drug, clinic, medicament, drugstore, treatment, ill, smiling, medicine, pharmaceutics, of, hospital,


Among the hedge funds from Insider Monkey’s database, seven were long Xenon Pharmaceuticals (NASDAQ:XENE) at the end of June, down from eight a quarter earlier. Some of the bullish investors contained Steve Cohen’s Point72 Asset Management, with a position valued at $2.12 million, and Jim Simons’ Renaissance Technologies, which held a position worth around $286,000.

Follow Xenon Pharmaceuticals Inc. (NASDAQ:XENE)
Trade (NASDAQ:XENE) Now!

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Biotechnology Value Trading Fund OS 0 262,664 0 262,664 262,664 1.5%
BVF Partners OS Ltd 0 262,664 0 262,664 262,664 1.5%
BVF Partners 0 3,108,905 0 3,108,905 3,108,905 17.9%
BVF Inc 0 3,108,905 0 3,108,905 3,108,905 17.9%
Mark N. Lampert 0 3,108,905 0 3,108,905 3,108,905 17.9%
Mark Lampert
Mark Lampert
Biotechnology Value Fund / BVF Inc

Page 1 of 10 – SEC Filing

Washington, D.C. 20549
(Rule 13d-102)


(Amendment No. 3)1
Xenon Pharmaceuticals Inc.
 (Name of Issuer)
Common Shares, no par value per share
 (Title of Class of Securities)
98420N 10 5
 (CUSIP Number)
September 8, 2016
 (Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
   o  Rule 13d-1(b)
   x  Rule 13d-1(c)
   o  Rule 13d-1(d)

The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
      The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.